U.S. markets closed
  • S&P Futures

    3,446.75
    +14.50 (+0.42%)
     
  • Dow Futures

    28,283.00
    +101.00 (+0.36%)
     
  • Nasdaq Futures

    11,719.50
    +58.75 (+0.50%)
     
  • Russell 2000 Futures

    1,619.90
    +5.10 (+0.32%)
     
  • Crude Oil

    41.44
    -0.26 (-0.62%)
     
  • Gold

    1,918.20
    +2.80 (+0.15%)
     
  • Silver

    25.06
    +0.08 (+0.32%)
     
  • EUR/USD

    1.1837
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    0.7970
    +0.0360 (+4.73%)
     
  • Vix

    29.35
    +0.17 (+0.58%)
     
  • GBP/USD

    1.2965
    +0.0018 (+0.14%)
     
  • USD/JPY

    105.3600
    -0.1100 (-0.10%)
     
  • BTC-USD

    12,016.50
    +959.49 (+8.68%)
     
  • CMC Crypto 200

    241.41
    +2.50 (+1.05%)
     
  • FTSE 100

    5,889.22
    +4.57 (+0.08%)
     
  • Nikkei 225

    23,628.35
    +61.31 (+0.26%)
     

P/E Ratio Insights for AstraZeneca

Benzinga Insights
·2 mins read

 

Looking into the current session, AstraZeneca Inc. (NYSE: AZN) is trading at $54.12, after a 2.8% drop. Over the past month, the stock fell by 3.55%, but over the past year, it actually increased by 19.52%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 16.66%.

The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company’s current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.

View more earnings on AZN

Most often, an industry will prevail in a particular phase of a business cycle, than other industries.

Compared to the aggregate P/E ratio of 15.15 in the Pharmaceuticals industry, AstraZeneca Inc. has a higher P/E ratio of 67.88. Shareholders might be inclined to think that AstraZeneca Inc. might perform better than its industry group. It’s also possible that the stock is overvalued.

P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.